rescheduled for early September. We would like to re‐extend a warm invitation to you both to attend this
rescheduled session and hope that you can provisionally indicate your interest.
We continue to see a role for young Europeans to play – leading with open and informed minds to help develop
short, medium and longer‐term solutions to help make health systems more sustainable, better able to prevent,
react, and recover from times of strain.
If you have any questions about the vaccine development or other initiatives that J&J is involved in, please do not
hesitate to come back to me.
For questions regarding the EHP, please reach out to the team here in copy who you already know well.
With very best wishes,
‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐
Begin forwarded message:
From:
[JPPBE]
To: "BUCHER Anne (SANTE)" <xxxx.xxxxxx@xx.xxxxxx.xx>
Cc:
[JPPBE] <
@its.jnj.com>;
[JPPBE]
@ITS.JNJ.com>;
[JPPBE] <
@its.jnj.com>;
[JPPBE] <
@its.jnj.com>
Subject: J&J Announces a Lead Vaccine Candidate for COVID‐19
J&J Announces a Lead Vaccine Candidate for COVID‐19
Dear Director General,
I sincerely hope you and your loved ones are doing well during these difficult times.
As I believe we share a common goal to contribute to a healthy Europe and given your crucial work in advancing the
well‐being of European citizens, I would like to share information with you regarding Johnson & Johnson’s efforts to
collaborate in the fight against COVID‐19.
This 30th of March, Johnson & Johnson announced the selection of a lead COVID‐19 vaccine candidate.
We are moving swiftly toward human clinical trials of the lead vaccine candidate by
and we
anticipate the first batches of a COVID‐19 vaccine could be available for emergency use authorization in
,
a substantially accelerated timeframe. For comparison: the typical vaccine development process involves a number
of different stages, ranging from 5 to 7 years before a candidate even qualifies for approval.
To upscale this effort, we have expanded our landmark partnership between the Janssen Pharmaceutical Companies
of Johnson & Johnson and the
. Together, we
have committed
of investment to co‐fund vaccine research, development and clinical testing.
J&J will expand its manufacturing capacity to ensure global supply of
doses of a safe and
effective vaccines worldwide. The Company plans to begin production at risk imminently and is committed to
bringing an affordable vaccine to the public on a not‐for‐profit basis for emergency pandemic use. The world is
facing an urgent public health crisis and we are committed to doing our part to make a COVID‐19 vaccine available
and affordable globally as quickly as possible.
We will also upscale Janssen’s ongoing efforts to identify new or existing treatments. We are working with global
partners to screen a library of existing antiviral molecules, with the aim of identifying compounds with promising
antiviral activity against the novel coronavirus, SARS‐CoV‐2 (also known as 2019‐nCoV) that could contribute to
providing immediate relief to the current outbreak. This work is being conducted in partnership with the
.
2
Square de Meeûs 23, 5th floor
BE‐1000 Brussels, Belgium
4